DaVita (DVA) expects to have gained from calcimimetics in the fourth quarter.
Thomas Burns became the CEO of Glaukos Corporation (NYSE:GKOS) in 2002. This analysis aims first to contrast CEO...
Glaukos Corp. (NYSE: GKOS) will replace AK Steel Holding Corp. (NYSE: AKS) in the S&P; SmallCap 600 effective prior to the open of trading on Friday, March 13. S&P; SmallCap 600 constituent Cleveland-Cliffs Inc. (NYSE: CLF) is acquiring AK Steel Holding in a transaction expected to be completed soon pending final conditions.
Image source: The Motley Fool. Glaukos (NYSE: GKOS)Q1 2020 Earnings CallMay 07, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorWelcome to Glaukos Corporation's first-quarter 2020 financial results conference call.
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Q4 2019 Glaukos Corp Earnings Call
Glaukos (GKOS) fourth-quarter results benefit from revenue growth. However, rise in operating expenses remains a concern.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
Glaukos Corporation (NYSE:GKOS), which is in the medical equipment business, and is based in United States, saw...
Glaukos (GKOS) witnessed a contraction in gross margin but year-over-year revenue surge in Q1.
BD's (BDX) core Life Sciences arm is expected to have driven first-quarter performance.
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various "on demand" presentations at the American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting, which will be held online on May 16-17, 2020.
Q1 2020 Glaukos Corp Earnings Call
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2020. Key highlights include:
With near-term visibility seeming bleak at the moment, we anticipate PAMA to once again dent LabCorp's (LH) fourth-quarter top line.
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2020 financial results after the market close on Thursday, May 7, 2020. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 7, 2020.
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today provided an update on the impact of the COVID-19 pandemic on the company and announced a preliminary net sales range for its first quarter of 2020.
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retina diseases, today provided an update on the actions it is taking in response to the COVID-19 pandemic.